ArticleNeuroradiology2026
Amide proton transfer and arterial spin labeling for non-invasive molecular stratification of glioma: a multi-dataset imaging biomarker study.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A dual-discriminator conditional generative adversarial network (DDcGAN) approach to glioma grade classification with structural MRI images fusion.Physical and engineering sciences in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate amide proton transfer chemical exchange saturation transfer magnetization transfer ratio asymmetry (MTRasym) and arterial spin labeling cerebral blood flow (CBF), two advanced MRI-based maps, for predicting glioma isocitrate dehydrogenase (IDH) mutation status, 1p/19q codeletion status, and grade using radiomics features; to assess cross-dataset/cross-vendor generalizability; and to examine whether combining MTRasym and CBF features improves prediction.
methodsThis multi-center study included 219 grade 2–4 glioma patients from three datasets (Netherlands/D1: n = 48, Siemens, prospective; Russia/D2: n = 42, Philips, retrospective; China/D3: n = 129, Siemens, retrospective). Descriptive and first-order radiomic features were analyzed from MTRasym (n = 219) and CBF maps (n = 90, CBF not available in D3), with and without normalization to contralateral regions of interest (ROI). Univariate diagnostic performance was assessed using area under the receiver operating characteristic (AUC) curves, random forest radiomics classifiers were evaluated using 5-fold cross-validation on D1 and subsequently validated externally on D2/D3. Combined MTRasym+CBF models were assessed on D1/D2 (n = 90).
resultsTumor-to-contralateral ROI-normalized ratios were comparable across sites (p > 0.05). Univariate MTRasym achieved AUCs of 0.94 (1p/19q), 0.87 (grade), and 0.76 (IDH); contralateral ROI-normalized CBF performed comparably for IDH (AUC = 0.77) and 1p/19q (AUC = 0.75), but not grade (AUC = 0.72). Radiomics models achieved AUCs of 0.91 (1p/19q), 0.81 (IDH), and 0.89 (grade) for MTRasym; combined MTRasym+CBF models significantly improved AUCs of 0.85 (IDH, p = 0.007) and 0.91 (grade, p = 0.001). External validation revealed MTRasym performed well on D3 (Siemens, same vendor), while normalized CBF generalized better than MTRasym to D2 (Philips).
conclusionMTRasym and CBF features show promise for glioma molecular stratification, and multimodal modeling improves predictions. Cross-vendor validation reveals modality-specific generalizability patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.